1124 related articles for article (PubMed ID: 34503440)
21. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
Sternberg A; McKee DL; Naujokat C
Curr Top Med Chem; 2020; 20(16):1423-1433. PubMed ID: 32416679
[TBL] [Abstract][Full Text] [Related]
22. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
23. Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2: A Combined in silico and in vitro Study.
Durdagi S; Orhan MD; Aksoydan B; Calis S; Dogan B; Sahin K; Shahraki A; Iyison NB; Avsar T
Mol Inform; 2022 Feb; 41(2):e2100062. PubMed ID: 34529322
[TBL] [Abstract][Full Text] [Related]
24. Molecular Insights into Small-Molecule Drug Discovery for SARS-CoV-2.
Su H; Zhou F; Huang Z; Ma X; Natarajan K; Zhang M; Huang Y; Su H
Angew Chem Int Ed Engl; 2021 Apr; 60(18):9789-9802. PubMed ID: 32729180
[TBL] [Abstract][Full Text] [Related]
25. Metal-Bound Methisazone; Novel Drugs Targeting Prophylaxis and Treatment of SARS-CoV-2, a Molecular Docking Study.
Abdelaal Ahmed Mahmoud M Alkhatip A; Georgakis M; Montero Valenzuela LR; Hamza M; Farag E; Hodgkinson J; Hosny H; Kamal AM; Wagih M; Naguib A; Yassin H; Algameel H; Elayashy M; Abdelhaq M; Younis MI; Mohamed H; Abdulshafi M; Elramely MA
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804129
[TBL] [Abstract][Full Text] [Related]
26. Potential SARS-CoV-2 protease M
Kouznetsova VL; Huang DZ; Tsigelny IF
Phys Biol; 2021 Feb; 18(2):025001. PubMed ID: 33203811
[TBL] [Abstract][Full Text] [Related]
27. Anisotine and amarogentin as promising inhibitory candidates against SARS-CoV-2 proteins: a computational investigation.
Kar P; Kumar V; Vellingiri B; Sen A; Jaishee N; Anandraj A; Malhotra H; Bhattacharyya S; Mukhopadhyay S; Kinoshita M; Govindasamy V; Roy A; Naidoo D; Subramaniam MD
J Biomol Struct Dyn; 2022 Jul; 40(10):4532-4542. PubMed ID: 33305988
[TBL] [Abstract][Full Text] [Related]
28. Potential antiviral properties of antiplatelet agents against SARS-CoV-2 infection: an in silico perspective.
Abosheasha MA; El-Gowily AH; Elfiky AA
J Thromb Thrombolysis; 2022 Feb; 53(2):273-281. PubMed ID: 34510337
[TBL] [Abstract][Full Text] [Related]
29. Repurposing nonnucleoside antivirals against SARS-CoV2 NSP12 (RNA dependent RNA polymerase): In silico-molecular insight.
Begum F; Srivastava AK; Ray U
Biochem Biophys Res Commun; 2021 Sep; 571():26-31. PubMed ID: 34303192
[TBL] [Abstract][Full Text] [Related]
30. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells.
Ko M; Jeon S; Ryu WS; Kim S
J Med Virol; 2021 Mar; 93(3):1403-1408. PubMed ID: 32767684
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment.
Jung LS; Gund TM; Narayan M
Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784
[TBL] [Abstract][Full Text] [Related]
32. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL
Jade D; Ayyamperumal S; Tallapaneni V; Joghee Nanjan CM; Barge S; Mohan S; Nanjan MJ
Eur J Pharmacol; 2021 Jun; 901():174082. PubMed ID: 33823185
[TBL] [Abstract][Full Text] [Related]
33. Tafenoquine and its derivatives as inhibitors for the severe acute respiratory syndrome coronavirus 2.
Chen Y; Yang WH; Chen HF; Huang LM; Gao JY; Lin CW; Wang YC; Yang CS; Liu YL; Hou MH; Tsai CL; Chou YZ; Huang BY; Hung CF; Hung YL; Wang WJ; Su WC; Kumar V; Wu YC; Chao SW; Chang CS; Chen JS; Chiang YP; Cho DY; Jeng LB; Tsai CH; Hung MC
J Biol Chem; 2022 Mar; 298(3):101658. PubMed ID: 35101449
[TBL] [Abstract][Full Text] [Related]
34. Repositioning of histamine H
Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
[TBL] [Abstract][Full Text] [Related]
35. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
Verma AK; Aggarwal R
Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
[TBL] [Abstract][Full Text] [Related]
36. A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2.
Wang S; Sun Q; Xu Y; Pei J; Lai L
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34081143
[TBL] [Abstract][Full Text] [Related]
37. Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19.
Talluri S
Comb Chem High Throughput Screen; 2021; 24(5):716-728. PubMed ID: 32798373
[TBL] [Abstract][Full Text] [Related]
38. iPSC screening for drug repurposing identifies anti-RNA virus agents modulating host cell susceptibility.
Imamura K; Sakurai Y; Enami T; Shibukawa R; Nishi Y; Ohta A; Shu T; Kawaguchi J; Okada S; Hoenen T; Yasuda J; Inoue H
FEBS Open Bio; 2021 May; 11(5):1452-1464. PubMed ID: 33822489
[TBL] [Abstract][Full Text] [Related]
39. An Overview of SARS-CoV-2 Potential Targets, Inhibitors, and Computational Insights to Enrich the Promising Treatment Strategies.
Kumawat P; Agarwal LK; Sharma K
Curr Microbiol; 2024 May; 81(7):169. PubMed ID: 38733424
[TBL] [Abstract][Full Text] [Related]
40. Identification of potent small molecule inhibitors of SARS-CoV-2 entry.
Mediouni S; Mou H; Otsuka Y; Jablonski JA; Adcock RS; Batra L; Chung DH; Rood C; de Vera IMS; Rahaim R; Ullah S; Yu X; Getmanenko YA; Kennedy NM; Wang C; Nguyen TT; Hull M; Chen E; Bannister TD; Baillargeon P; Scampavia L; Farzan M; Valente ST; Spicer TP
SLAS Discov; 2022 Jan; 27(1):8-19. PubMed ID: 35058179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]